Corbus Pharmaceuticals Holdings, Inc.
CRBP
$10.09
$0.010.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 90.26M | 74.27M | 70.10M | 60.48M | 50.42M |
| Gross Profit | -90.26M | -74.27M | -70.10M | -60.48M | -50.42M |
| SG&A Expenses | 16.62M | 15.57M | 15.22M | 15.47M | 16.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.88M | 89.84M | 85.31M | 75.95M | 67.04M |
| Operating Income | -106.88M | -89.84M | -85.31M | -75.95M | -67.04M |
| Income Before Tax | -101.90M | -84.53M | -78.54M | -67.51M | -57.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.90 | -84.53 | -78.54 | -67.51 | -57.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.90M | -84.53M | -78.54M | -67.51M | -57.95M |
| EBIT | -106.88M | -89.84M | -85.31M | -75.95M | -67.04M |
| EBITDA | -106.68M | -89.64M | -85.08M | -75.63M | -66.62M |
| EPS Basic | -6.18 | -5.81 | -5.98 | -5.51 | -4.76 |
| Normalized Basic EPS | -3.90 | -3.68 | -3.78 | -3.65 | -3.18 |
| EPS Diluted | -6.18 | -5.81 | -5.98 | -5.51 | -4.76 |
| Normalized Diluted EPS | -3.90 | -3.68 | -3.78 | -3.65 | -3.18 |
| Average Basic Shares Outstanding | 66.90M | 59.74M | 53.23M | 48.93M | 48.64M |
| Average Diluted Shares Outstanding | 66.90M | 59.74M | 53.23M | 48.93M | 48.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |